These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16617322)

  • 21. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
    Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
    Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Ohyashiki K; Ohyashiki JH
    Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
    Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
    Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
    Tan AY; Westerman DA; Dobrovic A
    Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
    Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
    Schaub FX; Jäger R; Looser R; Hao-Shen H; Hermouet S; Girodon F; Tichelli A; Gisslinger H; Kralovics R; Skoda RC
    Blood; 2009 Feb; 113(9):2022-7. PubMed ID: 19047681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The JAK2 V617F mutation is frequently present in buccal swabs from patients suffering from Philadelphia-negative chronic myeloproliferative disorders, who carry the mutation detected in bone marrow or peripheral blood cells [corrected].
    Stój A; Rudzki Z; Stachura J; Sacha T; Czekalska S
    J Clin Pathol; 2007 Sep; 60(9):1070-1. PubMed ID: 17761748
    [No Abstract]   [Full Text] [Related]  

  • 39. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
    Go RS
    Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.